Considerations for clinically-relevant nanomedicine therapies for chronic diseases

Nanomedicine

Volumn 10, Issue 20, 2015, Pages 3103-3107

  Owen, Andrew ^a   Rannard, Steve ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

chronic disease; nanocarriers; patient adherence; solid drug nanoparticles

Indexed keywords

CANCER THERAPY; CHRONIC DISEASE; HOLISTIC CARE; HUMAN; NANOMEDICINE; NOTE; PRIORITY JOURNAL; REGENERATIVE MEDICINE; TREATMENT OUTCOME; CHEMISTRY; DRUG DELIVERY SYSTEM; PROCEDURES;

DRUG CARRIER;

CHRONIC DISEASE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE;

EID: 84944206769     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.135     Document Type: Note

References (32)

1. Weissig V, Pettinger TK, Murdock N. Nanopharmaceuticals (part 1): products on the market. Int. J. Nanomedicine 9, 4357-4373 (2014).
2. Weissig V, Guzman-Villanueva D. Nanopharmaceuticals (part 2): products in the pipeline. Int. J. Nanomedicine 10, 1245-1257 (2015).
3. Boisseau P, Loubaton B. Nanomedicine, Nanotechnology in medicine. C. R. Phys. 12, 620-636 (2011).
4. Leskinen J, Joutsensaari J, Lyyränen J et al. Comparison of nanoparticle measurement instruments for occupational health applications. J. Nanopart. Res. 14, 718/1-718/16 (2012).
5. Wyatt PJ. Measurement of special nanoparticle structures by light scattering. Anal. Chem. 86, 7171-7183 (2014).
6. Barenholz Y. Doxil®-the first FDA-approved nano-drug: lessons learned. J. Control. Release 160, 117-134 (2012).
7. McDonald TO, Siccardi M, Moss D et al. The application of nanotechnology to drug delivery in medicine. In: Nano Engineering: Global Approaches to Health and Safety Issues. Dolez P (Ed.). Elsevier Health Sciences, Toronto, Canada, 173-223 (2015).
8. Matsumura Y, Oda T, Maeda H. General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics. Gan To Kagaku Ryoho 14, 821-829 (1987).
9. Nakamura H, Jun F, Maeda H. Development of nextgeneration macromolecular drugs based on the EPR effect: challenges and pitfalls. Expert Opin. Drug Deliv. 12, 53-64 (2015).
10. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomed. Nanotechnol. 9, 1-14 (2013).
11. Ebbesen M, Jensen TG. Nanomedicine: techniques, potentials, and ethical implications. J. Biomed. Biotechnol. 2006, 51516/1-51516/11 (2006).
12. Venditto VJ, Szoka FC. Cancer nanomedicines: so many papers and so few drugs! Adv. Drug Deliv. Rev. 65, 80-88 (2013).
13. Pridgen EM, Alexis F, Kuo TT et al. Transepithelial transport of Fc-targeted nanoparticles by the neonatal Fc receptor for oral delivery. Sci. Transl. Med. 5, 213ra167 (2013).
14. Escobar-Chávez JJ, Diáz-Torres R, Rodríguez-Cruz IM et al. Nanocarriers for transdermal drug delivery. Res. Rep. Transdermal Drug Deliv. 1, 3-17 (2012).
15. Hatton FL, Tatham LM, Tidbury LR et al. Hyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium. Chem. Sci. 6, 326-334 (2015).
16. Bernkop-Schnürch A. Nanocarrier systems for oral drug delivery: do we really need them? Eur. J. Pharm. Sci. 49, 272-277 (2013).
17. Hunter AC, Elsom J, Wibroe PP, Moghimi SM. Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. Nanomed. Nanotechnol. 8, S5-S20 (2012).
18. González-Rodríguez A, Catalán R, Penadés R et al. Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability-a review. Patient Prefer. Adherence 9, 695-706 (2015).
19. Boffito M, Jackson A, Owen A, Becker S. New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents. Drugs 74, 7-13 (2014).
20. Gaspar R, Duncan R. Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv. Drug Deliv. Rev. 61, 1220-1231 (2009).
21. European Medicines Agency Committee for Medicinal Products for Human Use. Reflection paper on nanotechnology-based medicinal products for human use. www.ema.europa.eu/docs/en-GB/document-library
22. Fanciullino R, Ciccolini J, Milano G. Challenges, expectations and limits for nanoparticles-based therapeuticsin cancer: a focus on nano-albumin-bound drugs. CRC Cr. Rev. Oncol. Hem. 88, 504-513 (2013).
23. Tatham LM, Rannard SP, Owen A. Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics. Ther. Deliv. 6, 469-490 (2015).
24. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J. Clin. Pharm. Ther. 26, 331-342 (2001).
25. Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: terminology and definitions. Value Health 11, 44-47 (2008).
26. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297, 177-186 (2007).
27. Weis SE, Slocum PC, Blais FX et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N. Engl. J. Med. 330, 1179-1184 (1994).
28. Schaecher KL. The importance of treatment adherence in HIV. Am. J. Manag. Care 19, s231-s237 (2013).
29. Winner B, Peipert JF, Zhao Q et al. Effectiveness of long-acting reversible contraception. N. Engl. J. Med. 366, 1998-2007 (2012).
30. Moses MA, Brem H, Langer R. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell 4, 337-341 (2003).
31. Smith TJ, Staats PS, Deer T et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J. Clin. Oncol. 20, 4040-4049 (2002).
32. Manickavasagam D, Oyewumi MO. Critical assessment of implantable drug delivery devices in glaucoma management. J. Drug Deliv. 2013, 895013 (2013).